Pyrazolo[3,4-c]pyridine derivatives
AssigneeCspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
InventorsYing SHI, Qingzhi GAO, Yi MI, Xuliang WANG
Life of this patent
Estimating the term…
Abstract
Disclosed are a compound of formula (I), a tautomer, an optical isomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the above-mentioned compounds. The above-mentioned compounds have the activity of inhibiting Xa factor positive effect, and can be used for the preparation of a medicament for preventing and/or treating diseases inhibiting Xa factor positive effect in case of low bleeding risk.
Claims21
-21. (canceled)
A compound of formula (I), a tautomer thereof, or an optical isomer thereof, or a pharmaceutically acceptable salt thereof:
- wherein
- X is selected from CH and N;
- Z is selected from
- RNa and RNb are each independently selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy-C0-6alkyl, (C0-6alkyl)(C0-6alkyl)N—C1-6alkyl, (C2-6alkylene)N—C1-6 alkyl or carbamoyl-C1-6alkyl;
- or
- RNa and RNb, together with the atoms attached thereto, form a 5, 6 or 7-membered cyclic moiety,
- wherein
- the 5, 6 or 7-membered cyclic moiety is substituted by one RNg, wherein the RNg is selected from hydrogen, C1-4alkyl, hydroxyl, C1-4alkoxy, halogen, oxo and amino,
- the 5, 6 or 7-membered cyclic moiety, besides the N atom attaching to RNb comprises 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S,
- the 5, 6 or 7-membered cyclic moiety comprises 0, 1, 2 or 3 double bonds;
- RNc is selected from hydrogen, C1-6alkyl and C1-6alkoxy;
- RNd is selected from hydrogen, C1-6alkoxy, halogen-substituted C1-6alkoxy, carbamoyl-C1-6alkyl and C1-6alkoxy-C1-6alkyl;
- RNe is selected from hydrogen, halogen, C1-6alkoxy, halogen-substituted C1-6alkoxy, carbamoyl-C1-6alkyl and C1-6alkoxy-C1-6alkyl;
- RNf is selected from hydrogen, halogen, C1-6alkoxy, halogen-substituted C1-6alkoxy, carbamoyl-C1-6alkyl and C1-6alkoxy-C1-6alkyl;
- with the proviso that the compound of formula (I) does not comprise the following compounds:
- 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopyridin-1(2H)-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- 1-(3-chlorophenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- 1-(3-chlorophenyl)-7-oxo-6-(4-(2-oxopyridin-1(2H)-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
- 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperazin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
A compound, a tautomer thereof, or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from:
Dependencies are inferred from the claim text.